Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung tumors and metastases to the lung. The study, entitled, “MicroRNA expression differentiates between primary lung tumors and metastases to the lung,” was published in the online edition of Pathology Research and Practice on April 28, 2010. The article is available at the following URL: see here.
Differentiating whether a pulmonary neoplasm is primary or metastatic can be challenging for surgical pathologists, and is an important distinction for clinicians in determining the proper treatment protocols. Current biomarkers do not always aid lung tumor classification. The study’s authors identified a set of microRNAs that is expressed differentially between these two groups using microRNA microarray data generated from 76 formalin-fixed, paraffin-embedded (FFPE) samples of either primary lung cancer or metastatic tumors to the lung.
According to the study, “The tissue-associated expression of microRNA likely explains the remarkable finding that many tumors can be classified based solely on their microRNA expression signature. Here we show that microRNAs can serve as biomarkers for lung tumor classification.”
“These data offer further evidence of the flexibility and potential wide range of clinical applicability of our microRNA technology. The growing body of literature, as well as our commercial line of miRview™ tests, continue to demonstrate that microRNAs are highly reliable and powerful biomarkers for a wide range of indications,” noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. …
MicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. The unique advantage of microRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19 to 21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. To learn more about microRNAs, please visit http://www.rosettagenomics.com .
About miRview™ Products
miRview™ products are a series of microRNA-based diagnostic tests developed by Rosetta Genomics. miRview™ mets accurately identifies the primary tumor site in metastatic cancer and Cancer of Unknown Primary (CUP) patients. miRview™ squamous accurately identifies the squamous subtype of NSCLC, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain targeted therapies. miRview™ meso diagnoses mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura. This test can be used to rule out mesothelioma in patients diagnosed with a tumor in the lung or pleura, who may have been exposed to asbestos in the past. miRview™ tests are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. The company’s tests are now being offered through distributors around the globe. For more information, please visit http://www.mirviewdx.com .